Draft:Terry Pirovolakis
| Submission declined on 6 June 2024 by Qcne (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies. The content of this submission includes material that does not meet Wikipedia's minimum standard for inline citations. Please cite your sources using footnotes. For instructions on how to do this, please see Referencing for beginners. Thank you.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Terry Pirovolakis (born 1979) is a Canadian technologist and biotech leader focused on developing treatments for ultra-rare disorders. He has spent much of his career in IT, building call centers and CRM systems for Fortune 500 companies worldwide. In 2019, his youngest son, Michael, was diagnosed with SPG50, an ultra-rare disease. In response, Terry and his family founded CureSPG50 to raise funds for research and treatment for this condition, which affects fewer than 200 children globally.[1] Within three years, they raised $4.5 million and developed a treatment for Michael and others with SPG50. Following this achievement, Terry founded Elpida Therapeutics SPC, a biotech company run as a non-profit, dedicated to providing gene therapies to children in need worldwide.
References[edit]
- https://www.cbc.ca/news/health/a-race-against-time-toronto-family-tries-to-raise-3m-to-treat-son-s-rare-genetic-disorder-1.5218632
- https://www.cbc.ca/news/canada/toronto/toronto-family-genetic-disorder-clinical-trial-1.6550306
- https://www.cbc.ca/news/health/medical-fundraising-boot-camp-rare-disease-1.5292192
- 'There's no stopping': Family of boy treated for rare genetic disease looks to cure others
- ‘Uncharted territory’: Toronto family of child with rare disease raises $3M for therapy | Globalnews.ca
- Parents Are Racing to Find a Cure for This 19 Month Old: 'I'm Not Going to Let My Son Wither Away'
- Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials
- Canadian family raised $3.5M to develop individualized gene therapy for son's rare condition | National Post
- Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies
- Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies
- Paving a way to treat spastic paraplegia 50
- ^ Roumeliotis, Ioanna; Mancini, Melissa. "'A race against time': Toronto family tries to raise $3M to treat son's rare genetic disorder".